Trial Profile

A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions

Most Recent Events

04 Jul 2023 Results assessing long-term outcomes for stage III/IV melanoma patients treated with neoadjuvant and adjuvant PD-1 inhibition, published in the Annals of Oncology.
14 Dec 2021 Status changed from active, no longer recruiting to completed.
01 Feb 2021 Results (n=192) of a pooled analysis of six trials (NCT02231775, NCT01972347, NCT02437279, NCT02519322, NCT02434354and NCT02977052) assessing pathological response and survival with neoadjuvant therapy in melanoma, published in the Nature Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com